Literature DB >> 22488244

Effects of SASH1 on lung cancer cell proliferation, apoptosis, and invasion in vitro.

En-guo Chen1, Yanfan Chen, Liang-liang Dong, Ji-song Zhang.   

Abstract

The purposes of this study were to investigate the effects of the SASH1 gene on the growth, proliferation, apoptosis, invasiveness, and metastatic potential of lung cancer cells and explore the potential use of SASH1 for the treatment of human lung cancer. The SASH1 gene was cloned into the pcDNA3.1 eukaryotic expression vector, and SASH1 shRNA were designed and constructed. The resulting constructs were transfected into A549 human lung cancer cells, and the changes in the relevant biological characteristics of the cells overexpressing SASH1 and cells with downregulated expression of SASH1 were analyzed using the MTT assay, transwell invasion assay, and flow cytometry. The effects of the SASH1 gene on the expression of cyclin D1, Bcl-2, and MMP-2/9 were also concurrently examined. In the A549 cells from the pcDNA3.1-SASH1 transfected group, cell viability, proliferation, and migration were significantly reduced compared to the control cells (p = 0.039, p = 0.013), and a cell cycle arrest in G1 was observed. The A549 cells transfected with the SASH1 shRNA demonstrated significantly higher cell viabilities, proliferation, and migration compared to the control cells (p = 0.012, p = 0.045). Additionally, the percentage of A549 cells undergoing apoptosis was significantly higher in the pcDNA3.1-SASH1 transfected cells and significantly lower in the SASH1 shRNA transfected cells compared to the control cells (p = 0.010, p = 0.000). The cyclin D1, Bcl-2, and MMP-9/2 protein expression levels were significantly lower in the pcDNA3.1-SASH1-transfected cells and were significantly higher in the SASH1 shRNA-transfected cells than that in the control cells. The SASH1 gene may inhibit A549 cell growth and proliferation as well as promote cellular apoptosis. The overexpression of the SASH1 gene may also be related to the decreased migration of A549 human lung cancer cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22488244     DOI: 10.1007/s13277-012-0387-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

Review 1.  UV-radiation, apoptosis and skin.

Authors:  Nives Pustisek; Mirna Situm
Journal:  Coll Antropol       Date:  2011-09

Review 2.  Circulating soluble intercellular adhesion molecule-1 in lung cancer: a systematic review.

Authors:  Xiaoling Gu; Chunyan Ma; Dongmei Yuan; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2012-03

3.  Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor α5β1 in the process.

Authors:  Triparna Sen; Amitava Chatterjee
Journal:  Eur J Nutr       Date:  2010-12-19       Impact factor: 5.614

4.  Mutational analysis of tumour suppressor gene NF2 in common solid cancers and acute leukaemias.

Authors:  Nam Jin Yoo; Sang Wook Park; Sug Hyung Lee
Journal:  Pathology       Date:  2012-01       Impact factor: 5.306

5.  HACS1 encodes a novel SH3-SAM adaptor protein differentially expressed in normal and malignant hematopoietic cells.

Authors:  J O Claudio; Y X Zhu; S J Benn; A H Shukla; C J McGlade; N Falcioni; A K Stewart
Journal:  Oncogene       Date:  2001-08-30       Impact factor: 9.867

Review 6.  Advances on EGFR mutation for lung cancer.

Authors:  Giulio Metro; Lucio Crinò
Journal:  Transl Lung Cancer Res       Date:  2012-03

Review 7.  Angiogenesis in cancer: Anti-VEGF escape mechanisms.

Authors:  Gerald W Prager; Marina Poettler; Matthias Unseld; Christoph C Zielinski
Journal:  Transl Lung Cancer Res       Date:  2012-03

8.  EMMPRIN contributes to the in vitro invasion of human salivary adenoid cystic carcinoma cells.

Authors:  Xinjie Yang; Pu Zhang; Qin Ma; Liang Kong; Yuan Li; Baolin Liu; Delin Lei
Journal:  Oncol Rep       Date:  2011-12-22       Impact factor: 3.906

9.  A common genetic variant (97906C>A) of DAB2IP/AIP1 is associated with an increased risk and early onset of lung cancer in Chinese males.

Authors:  Lei Yang; Yinyan Li; Xiaoxuan Ling; Lin Liu; Bin Liu; Kevin Xu; Xiaonong Bin; Weidong Ji; Jiachun Lu
Journal:  PLoS One       Date:  2011-10-26       Impact factor: 3.240

10.  Essential role of protein kinase C zeta in transducing a motility signal induced by superoxide and a chemotactic peptide, fMLP.

Authors:  Kageaki Kuribayashi; Kiminori Nakamura; Maki Tanaka; Tsutomu Sato; Junji Kato; Katsunori Sasaki; Rishu Takimoto; Katsuhisa Kogawa; Takeshi Terui; Tetsuji Takayama; Takayuki Onuma; Takuya Matsunaga; Yoshiro Niitsu
Journal:  J Cell Biol       Date:  2007-03-26       Impact factor: 10.539

View more
  15 in total

1.  SASH1 inhibits proliferation and invasion of thyroid cancer cells through PI3K/Akt signaling pathway.

Authors:  Dawei Sun; Rui Zhou; Huamin Liu; Wenhai Sun; Anbing Dong; Hongmei Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  Influence of Smoking Status and Intensity on Discovery of Blood Pressure Loci Through Gene-Smoking Interactions.

Authors:  Jacob Basson; Yun Ju Sung; Lisa de Las Fuentes; Karen Schwander; L Adrienne Cupples; D C Rao
Journal:  Genet Epidemiol       Date:  2015-05-03       Impact factor: 2.135

3.  Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.

Authors:  Xi Chen; Yixiao Yuan; Wenjun Ren; Fan Zhou; Xiaobin Huang; Jun Pu; Xiaoqun Niu; Xiulin Jiang
Journal:  Front Oncol       Date:  2022-06-03       Impact factor: 5.738

4.  Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma.

Authors:  Jean-Benoît Courcet; Siham Chafai Elalaoui; Laurence Duplomb; Mariam Tajir; Jean-Baptiste Rivière; Julien Thevenon; Nadège Gigot; Nathalie Marle; Bernard Aral; Yannis Duffourd; Alain Sarasin; Valeria Naim; Emilie Courcet-Degrolard; Marie-Hélène Aubriot-Lorton; Laurent Martin; Jamal Eddin Abrid; Christel Thauvin; Abdelaziz Sefiani; Pierre Vabres; Laurence Faivre
Journal:  Eur J Hum Genet       Date:  2014-10-15       Impact factor: 4.246

5.  The adaptor SASH1 acts through NOTCH1 and its inhibitor DLK1 in a 3D model of lumenogenesis involving CEACAM1.

Authors:  Kandis Stubblefield; Jennifer Chean; Tung Nguyen; Charng-Jui Chen; John E Shively
Journal:  Exp Cell Res       Date:  2017-08-18       Impact factor: 3.905

6.  Clinical Significance of SASH1 Expression in Glioma.

Authors:  Liu Yang; Haitao Zhang; Qi Yao; Yingying Yan; Ronghua Wu; Mei Liu
Journal:  Dis Markers       Date:  2015-09-06       Impact factor: 3.434

7.  SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype.

Authors:  Yiqun G Shellman; Karoline A Lambert; Anne Brauweiler; Pamela Fain; Richard A Spritz; Melanie Martini; Klaus-Peter Janssen; Neil F Box; Tamara Terzian; Marian Rewers; Anelia Horvath; Constantine A Stratakis; William A Robinson; Steven E Robinson; David A Norris; Kristin B Artinger; Theresa R Pacheco
Journal:  J Invest Dermatol       Date:  2015-07-23       Impact factor: 8.551

8.  SASH1 mediates sensitivity of breast cancer cells to chloropyramine and is associated with prognosis in breast cancer.

Authors:  Joshua T Burgess; Emma Bolderson; Jodi M Saunus; Shu-Dong Zhang; Lynne E Reid; Anne Marie McNicol; Sunil R Lakhani; Katharine Cuff; Kerry Richard; Derek J Richard; Kenneth J O'Byrne
Journal:  Oncotarget       Date:  2016-11-08

9.  Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response.

Authors:  Joshua T Burgess; Emma Bolderson; Mark N Adams; Anne-Marie Baird; Shu-Dong Zhang; Kathy A Gately; Kazuo Umezawa; Kenneth J O'Byrne; Derek J Richard
Journal:  Cell Death Dis       Date:  2016-11-10       Impact factor: 8.469

Review 10.  Role of exosomes in malignant glioma: microRNAs and proteins in pathogenesis and diagnosis.

Authors:  Amir B Ghaemmaghami; Maryam Mahjoubin-Tehran; Ahmad Movahedpour; Korosh Morshedi; Amirhossein Sheida; Seyed Pouya Taghavi; Hamed Mirzaei; Michael R Hamblin
Journal:  Cell Commun Signal       Date:  2020-08-03       Impact factor: 7.525

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.